Genomics — Timeline

Timeline

Key developments in precision gene editing and longevity, ordered chronologically (most recent at the bottom).

DateEventSignificanceSource
2006Yamanaka factors publishedFour genes (OSKM) reprogram adult cells to pluripotent state — Nobel-winning foundation for aging-reversal researchLife Biosciences FDA
2016Base editing published (David Liu, Broad Institute)First genome editing without double-strand breaks — direct C-to-T base conversionPrime Editing Suppressor tRNAs
2019Prime editing published (David Liu, Broad Institute)Search-and-replace genome editing — all 12 point mutations, small insertions/deletions without DNA breaksPrime Editing Suppressor tRNAs
2020Sinclair mouse optic nerve paper (Nature)Partial OSK reprogramming restored vision in mice — foundational preclinical data for 2026 Life Biosciences trialLife Biosciences FDA
Dec 2023Casgevy approved (first CRISPR therapy)FDA/MHRA approval for Sickle Cell and beta-thalassemia — gene editing enters clinical medicineCRISPR Cholesterol Trial
Apr 2024OpenCRISPR-1 public releaseProfluent releases first AI-designed CRISPR editor publicly, pre-publicationOpenCRISPR-1
Apr 2024First FDA-approved prime editing trial beginsPrime editing moves from laboratory to human patientsPrime Editing Suppressor tRNAs
Jun 2024 – Aug 2025ANGPTL3 cholesterol trial enrollmentCleveland Clinic Phase 1, 15 patients for CTX310 CRISPR cholesterol trialCRISPR Cholesterol Trial
Jul 2025OpenCRISPR-1 published in NatureFully AI-designed gene editor edits human genome, 95% off-target reduction vs SpCas9OpenCRISPR-1
Sep 2025CRISPR-GPT published (Stanford)LLM copilot for gene editing — novice first-attempt successCRISPR-GPT
Nov 2025Prime editing suppressor tRNAs (Nature)Disease-agnostic approach for ~30% of rare diseases. Liu, 2025 Breakthrough PrizePrime Editing Suppressor tRNAs
Nov 2025ANGPTL3 cholesterol trial resultsLDL -50%, triglycerides -55%, sustained 60+ daysCRISPR Cholesterol Trial
Nov 2025Profluent raises $106MMarket validation of generative biology platformOpenCRISPR-1
Dec 2025Baylor precision longevity review (Frontiers)Single-cell atlas framework for cell-type-specific aging interventionsPrecision Longevity
Jan 2026Epigenetic editing without DNA cuts (UNSW/St Jude)Demethylation-based Sickle Cell gene reactivationEpigenetic Editing
Jan 2026Life Biosciences FDA approvalFirst-in-human trial of partial OSK reprogramming — Phase 1 glaucoma + NAION, ~12 patientsLife Biosciences FDA
Apr 2026Ledford Nature commentary on Life BiosciencesMajor skeptic voices surface: Gladyshev, Williams, Chandra warn on cancer + cell-identity risksLedford Nature
2026 (coming months)Life Biosciences first patientsPhase 1 dosing begins; readout expected late 2026 / early 2027Life Biosciences FDA
Feb 2025Multiplexed in vivo base editing (bioRxiv)Functional genomics platform — systematic gene-variant-context interaction mapping in vivoMultiplexed base editing
Dec 2025Vertex CASGEVY pediatric data (ASH)First clinical data in children ages 5-11; 1H 2026 global regulatory submissions plannedCASGEVY pediatric
Feb 2026RBM20 cardiac prime editing (bioRxiv)First in vivo cardiac prime editing with tissue specificity — heart edited, no liver editing. Cardiomyopathy phenotype rescueRBM20 cardiac prime editing
Dec 2025Single-cell long-read sequencing review (Briefings in Bioinformatics)SCLR-seq matures: PacBio HiFi 99.9–99.95% + ONT ~99%; single-cell + long-read convergence moves transcriptomics to isoform-level resolutionSCLR-seq review
Mar 2025Beam BEAM-302 first-ever genetic correction in AATD patientsIn vivo base editing corrects the PiZ mutation; dose-dependent durable AAT increase — base editing reaches human correctionBeam clinical 2026
Apr 2026Intellia HAELO Phase 3 success (lonvo-z)First in vivo CRISPR therapy to clear Phase 3 — single 50 mg dose cut HAE attacks 87% vs placebo (p<0.0001), 62% attack-free. Rolling BLA; US launch target 1H 2027Intellia HAELO Phase 3
Jun 2026FDA clears BEAM-304 IND for PKUIn vivo adenine base editing of PAH (R408W) — corrective therapy aiming at dietary liberalization for phenylketonuriaBeam clinical 2026
Timeline — Genomics | KB | MenFem